Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 197,020
  • Shares Outstanding, K 209,596
  • Annual Sales, $ 194,620 K
  • Annual Income, $ -51,930 K
  • 60-Month Beta 0.80
  • Price/Sales 1.09
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade AKBA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.23
  • Most Recent Earnings $-0.09 on 05/09/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 85.08% ( -48.57%)
  • Historical Volatility 56.36%
  • IV Percentile 2%
  • IV Rank 2.12%
  • IV High 766.96% on 10/05/23
  • IV Low 70.30% on 05/06/24
  • Put/Call Vol Ratio 0.13
  • Today's Volume 247
  • Volume Avg (30-Day) 234
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 33,609
  • Open Int (30-Day) 33,217

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.07
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.08
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9025 +4.76%
on 06/21/24
1.1950 -20.88%
on 06/13/24
-0.1845 (-16.33%)
since 05/21/24
3-Month
0.9025 +4.76%
on 06/21/24
2.4800 -61.88%
on 03/28/24
-1.0945 (-53.65%)
since 03/21/24
52-Week
0.7801 +21.20%
on 10/26/23
2.4800 -61.88%
on 03/28/24
-0.1445 (-13.26%)
since 06/21/23

Most Recent Stories

More News
Akebia Therapeutics: Q1 Earnings Snapshot

Akebia Therapeutics: Q1 Earnings Snapshot

AKBA : 0.9492 (+0.98%)
Akebia Therapeutics: Q3 Earnings Snapshot

Akebia Therapeutics: Q3 Earnings Snapshot

AKBA : 0.9492 (+0.98%)
Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023

/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 0.9492 (+0.98%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 0.9492 (+0.98%)
Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat

/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 0.9492 (+0.98%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 0.9492 (+0.98%)
Gap, Hibbett rise; Hawaiian Electric, Nordstrom fall, Friday, 8/25/2023

Stocks that are trading heavily or have substantial price changes Friday: Gap, Hibbett rise; Hawaiian Electric, Nordstrom fall

JWN : 21.02 (-0.85%)
DOMO : 6.76 (-2.03%)
WDAY : 219.36 (+2.22%)
AKBA : 0.9492 (+0.98%)
GPS : 24.39 (-3.21%)
HE : 9.41 (+1.40%)
Akebia Therapeutics: Q2 Earnings Snapshot

Akebia Therapeutics: Q2 Earnings Snapshot

AKBA : 0.9492 (+0.98%)
Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 0.9492 (+0.98%)
Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023

/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 0.9492 (+0.98%)

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 1.0657
2nd Resistance Point 1.0403
1st Resistance Point 0.9902
Last Price 0.9492
1st Support Level 0.9147
2nd Support Level 0.8893
3rd Support Level 0.8392

See More

52-Week High 2.4800
Fibonacci 61.8% 1.8306
Fibonacci 50% 1.6300
Fibonacci 38.2% 1.4295
Last Price 0.9492
52-Week Low 0.7801

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar